The chief executive of Covid-19 vaccine pioneer BioNTech said he does not expect for now that new oral treatments against the viral infection would considerably reduce demand for vaccines.
The United States on Nov. 3 started vaccinating children aged 5 to 11 against Covid-19, with roughly 28 million school-age kids now eligible for the shots that provide protection against the illness.
Advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Nov. 2 unanimously supported broad use of Pfizer and BioNTech’s Covid-19 vaccine in children ages 5 to 11, with shots potentially going into young arms as soon as Nov. 3.
Pfizer Inc. on Nov. 2 said the company expected 2021 sales of the Covid-19 vaccine developed with German partner BioNTech SE would reach $36 billion and forecast another $29 billion from the shot in 2022, topping analyst estimates for both years.
The United States is rolling out Pfizer/BioNTech Covid-19 vaccines for children aged 5 to 11 this week, but most of the 15 million shots being shipped initially are unlikely to be available before next week, the White House said on November 1.
The U.S. Food and Drug Administration on Oct. 29 authorized the Pfizer Inc. and BioNTech SE coronavirus vaccine for children aged 5 to 11 years, making it the first COVID-19 shot for young children in the United States.
In the face of Delta, the actual efficacy of Covid-19 vaccines in a real-world setting has come into question even if they still appear to be very close to 100 percent at preventing death or severe disease, which is the primary goal of a vaccine. Studies suggest that Moderna’s Covid-19 vaccine appears better than the Pfizer-BioNTech vaccination in terms of antibody count and prevention of hospitalizations, and both were significantly more effective than Johnson & Johnson’s shot.
An advisory panel of the U.S. Centers for Disease Control and Prevention will meet on Nov. 2 to discuss the use of Covid-19 vaccines in children aged between 5 and 11 years.
The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee recommended emergency use authorization (EUA) for the Pfizer-BioNTech vaccine for children 5 through 11 years of age, with 17 members voting yes and one abstention.
The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee is meeting Oct. 26 to discuss and recommend an emergency use authorization for the Pfizer-BioNTech vaccine for children 5 through 11 years of age.
